Karyopharm Therapeutics (KPTI) Treasury Shares (2012 - 2025)

Karyopharm Therapeutics has reported Treasury Shares for 13 years, with the latest figure at $1.3 million in Q4 2025.

• For the quarter ending Q4 2025, Treasury Shares rose 55.59% year-over-year to $1.3 million; the trailing twelve-month figure through Dec 2025 stood at $1.3 million (up 55.59% YoY), and the FY2025 full-year result was $1.3 million, up 55.59% from the prior year.
• Treasury Shares for Q4 2025 stood at $1.3 million, up from $850738.0 in the prior quarter.
• The five-year high for Treasury Shares was $7.7 million in Q4 2023, with the low at $850738.0 in Q4 2024.
• Historically, Treasury Shares has averaged $3.1 million across 5 years, with a median of $2.3 million in 2021.
• Annual changes were most pronounced in 2023 — Treasury Shares surged 125.3% — and 2024, when it sank 88.9%.
• Karyopharm Therapeutics' Treasury Shares stood at $2.3 million in 2021, then surged by 47.91% to $3.4 million in 2022, then soared by 125.3% to $7.7 million in 2023, then slumped by 88.9% to $850738.0 in 2024, then soared by 55.59% to $1.3 million in 2025.
• The last three Treasury Shares figures came in at $1.3 million (Q4 2025), $850738.0 (Q4 2024), and $7.7 million (Q4 2023), per Business Quant data.